skip to content
  1. Home
  2. >
  3. Questions
  4. >
  5. GUD: Your comments on Knight's first quarter results? [Knight Therapeutics Inc.]
You can view 2 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Your comments on Knight's first quarter results?
Thanks
Asked by Lawrence on May 16, 2023
5i Research Answer:

EPS of ($0.04) beat estimates of ($0.0451) and revenues of $82.6M beat estimates of $74.98M. Sales grew by 29%, and its gross margins contracted slightly from 51% in the prior year to 49%. Its Adjusted EBITDA grew by 37%, and the company purchased ~2.2M shares in the quarter. The company was able to expand its Adjusted EBITDA margins as it managed its operating expenses well and leveraged its high sales growth rate. It has been mostly using its free cash flows to repurchase shares, and the stock remains at a good valuation, but the company may struggle to get a great valuation in the market and for now its momentum has been fairly muted.